Phase I study of RO4929097, a gamma secretase inhibitor of notch signaling, in patients with refractory metastatic or locally advanced solid tumors

Journal of Clinical Oncology

Volumn 30, Issue 19, 2012, Pages 2348-2353

  Tolcher, Anthony W ^a   Messersmith, Wells A ^c   Mikulski, Stanislaw M ^d   Papadopoulos, Kyriakos P ^a   Kwak, Eunice L ^f   Gibbon, Darlene G ^e   Patnaik, Amita ^a   Falchook, Gerald S ^b   Dasari, Arvind ^c   Shapiro, Geoffrey I ^g   Boylan, John F ^d   Xu, Zhi Xin ^d   Wang, Ka ^d   Koehler, Astrid ^h   Song, James ^d   Middleton, Steven A ^d   Deutsch, Jonathan ^d   DeMario, Mark ^d   Kurzrock, Razelle ^b   Wheler, Jennifer J ^b  

^a Center for Cancer Care   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; CYTOCHROME P450 3A4; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 6; MIDAZOLAM; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; PHOSPHATE; TRANSCRIPTION FACTOR HES 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CHILL; COLORECTAL CARCINOMA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HAIR LEVEL; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; PHOSPHATE URINE LEVEL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; QT PROLONGATION; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID PRECURSOR PROTEIN SECRETASES; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84864018642     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.8282     Document Type: Article

References (10)

1. Miele L, Miao H, Nickoloff BJ: NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6:313-323, 2006. (Pubitemid 43961866)
2. Bolós V, Grego-Bessa J, de la Pompa JL: Notch signaling in development and cancer. Endocr Rev 28:339-363, 2007 (Pubitemid 46984831)
3. Bray SJ: Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol 7:678-689, 2006
4. Luistro L, He W, Smith M, et al: Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 69:7672-7680, 2009
5. Borggrefe T, Oswald F: The Notch signaling pathway: Transcriptional regulation at Notch target genes. Cell Mol Life Sci 66:1631-1646, 2009
6. D'Souza B, Miyamoto A, Weinmaster G: The many facets of Notch ligands. Oncogene 27:5148-5167, 2008
7. Rizzo P, Osipo C, Foreman K, et al: Rationale targeting of Notch signaling in cancer. Oncogene 27:5124-5131, 2008
8. Phng LK, Gerhardt H: Angiogenesis: A team effort coordinated by notch. Dev Cell 16:196-208, 2009
9. Dufraine J, Funahashi Y, Kitajewski J: Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 27:5132-5137, 2008
10. Center for Drug Evaluation and Research (CDER): Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, July 2005